Commercial Activities
The commercial strategy adopted by CRCBID can be briefly summarised as a four-stage process flowing from proof of concept to an established and growing position in the marketplace.
Through its R&D into novel radiotracers and improved detectors, CRCBID expects to create a wide array of commercial opportunities for Australian companies and other organisations to capture a share of new or existing markets in the medical imaging industry, here and overseas.
Among the opportunities identified to date are the:- Production and supply of non-radioactive chemical precursors for the synthesis of the radiotracers;
- Manufacture of ‘bolt-on’ chemistry modules and control software for existing synthesis systems to produce new radiotracers;
- Manufacture and supply of next-generation (smaller, more efficient and cheaper) synthesis systems for on-site production of current and new radiotracers;
- Manufacture of integrated detector sub-systems and software to imaging equipment suppliers for incorporation into next-generation traditional and functional imaging systems;
- Assembly and integration of pixel array detectors.
- Provision of customised imaging solutions.
In addition, it is envisaged CRCBID's research program will contribute towards the development of platform technologies that will enhance Australia's attractiveness as a location for clinical trials of drug candidates—potentially worth hundreds of millions of dollars a year.
